FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

6 Observations in Aurobindo Inspection

[ Price : $8.95]

Aurobindo reports receiving a six-item FDA 483 after an inspection at its Unit VII oral drug manufacturing unit in Jadcherla, Hyde...

QSR Proposed Revisions Will Advance Harmonization: Post

[ Price : $8.95]

Pharmatech Associates managing director Stephanie Gaulding discusses the effects of an FDA proposed revision to the medical device...

BMS Updates Psoriasis Drug Safety/Efficacy

[ Price : $8.95]

Bristol Myers Squibb provides two-year results from its POETYK PSO long-term extension trial of deucravacitinib in adult patients ...

Meeting on User Fee Financial Transparency

[ Price : $8.95]

Federal Register notice: FDA announces a 6/7 public meeting entitled Financial Transparency and Efficiency of the Prescription Dru...

Appeals Court Decision Hurts Drug Research Incentives: FDA

[ Price : $8.95]

FDA says an appeals court decision in a case involving orphan drug exclusivity is likely to slow research and innovation into drug...

Can Development Time be Cut 50% From Covid Lessons?

[ Price : $8.95]

CBER director Peter Marks says he wants to continue the Operation Warp Speed attention and quick approval process given to Covid-1...

Lou Gehrigs Drug Now in Oral Suspension

[ Price : $8.95]

FDA approves an oral suspension formulation of Mitsubishi Tanabe Pharma Americas Radicava (edaravone) for treating adults with amy...

FDA Extends PDUFA Dates for Amicus AT-GAA NDA, BLA

[ Price : $8.95]

FDA extends for 90 days the PDUFA review action dates for Amicus BLA and NDA for components of its AT-GAA, intended to treat late-...

Monitor Cybersecurity Regulation Developments: Attorneys

[ Price : $8.95]

Ropes & Gray attorneys see increasing cybersecurity expectations for medical device manufacturers in FDA regulations and congressi...

Data Reinforce Nirsevimab RSV Efficacy: Sanofi/AstraZeneca

[ Price : $8.95]

Sanofi and AstraZeneca say additional Phase 3 and Phase 2b trial data continue to demonstrate nirsevimab efficacy against respirat...